SBFM
NBIX icon

S-Bank Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

S-Bank Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-885
Closed -$117K – 278
2026
Q1 		$117K Sell
885
-33
-4% -$4.38K 0.02% 159
2025
Q4 		$130K Sell
918
-35
-4% -$5.07K 0.02% 156
2025
Q3 		$134K Sell
953
-12
-1% -$1.63K 0.02% 186
2025
Q2 		$121K Sell
965
-327
-25% -$37.5K 0.02% 191
2025
Q1 		$143K Buy
+1,292
New +$164K 0.03% 163

Other funds holding NBIX

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
SCP
Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

S-Bank Fund Management's NBIX Position: Q2 2026 in Review

S-Bank Fund Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 885 shares — an estimated $117K sold.

S-Bank Fund Management first reported a position in NBIX in Q1 2025 and held it in 5 quarters. The position peaked at $143K in Q1 2025. 342 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • S-Bank Fund Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • S-Bank Fund Management sold 885 Neurocrine Biosciences shares in Q2 2026, an estimated $117K.
  • S-Bank Fund Management first reported a position in Neurocrine Biosciences in Q1 2025 and held it in 5 quarters.
  • S-Bank Fund Management's Neurocrine Biosciences position peaked at $143K in Q1 2025.
  • 342 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on S-Bank Fund Management's 13F filing for Q2 2026, filed 4 Aug 2026.